{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:10:58Z","timestamp":1780333858329,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI113127"],"award-info":[{"award-number":["AI113127"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10461-018-2211-5","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T10:14:39Z","timestamp":1530612879000},"page":"252-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies"],"prefix":"10.1007","volume":"23","author":[{"given":"Wutyi S.","family":"Aung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul P.","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Breakey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Weld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"2211_CR1","unstructured":"UNAIDS. Global AIDS update. 2016. \n                    http:\/\/aidsinfo.unaids.org\/\n                    \n                  . Accessed 24 May 2018."},{"issue":"27","key":"2211_CR2","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","journal-title":"N Engl J Med"},{"issue":"6","key":"2211_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493\u2013505.","journal-title":"N Engl J Med"},{"issue":"5","key":"2211_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2211_CR5","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1093\/cid\/ciu266","volume":"59","author":"KR Amico","year":"2014","unstructured":"Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(Suppl 1):S55\u201360.","journal-title":"Clin Infect Dis"},{"key":"2211_CR6","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.1000730","author":"L Goparaju","year":"2017","unstructured":"Goparaju L, Praschan NC, Warren-Jeanpiere L, et al. Stigma, partners, providers and costs: potential barriers to PrEP uptake among US women. J AIDS Clin Res. 2017. \n                    https:\/\/doi.org\/10.4172\/2155-6113.1000730\n                    \n                  .","journal-title":"J AIDS Clin Res."},{"issue":"11","key":"2211_CR7","doi-asserted-by":"publisher","first-page":"e005717","DOI":"10.1136\/bmjopen-2014-005717","volume":"4","author":"I Young","year":"2014","unstructured":"Young I, Flowers P, McDaid LM. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open. 2014;4(11):e005717. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2014-005717\n                    \n                  .","journal-title":"BMJ Open"},{"issue":"1","key":"2211_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s10461-012-0172-7","volume":"17","author":"AB Williams","year":"2013","unstructured":"Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284\u201397.","journal-title":"AIDS Behav"},{"key":"2211_CR9","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s10461-013-0429-9","volume":"17","author":"KR Amico","year":"2013","unstructured":"Amico KR, Mansoor LE, Corneli A, et al. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143\u201355.","journal-title":"AIDS Behav"},{"issue":"1","key":"2211_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1089\/aid.2015.0182","volume":"32","author":"CW Hendrix","year":"2016","unstructured":"Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retrovir. 2016;32(1):32\u201343.","journal-title":"AIDS Res Hum Retrovir."},{"key":"2211_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-17","author":"PL Anderson","year":"2017","unstructured":"Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2017. \n                    https:\/\/doi.org\/10.1128\/AAC.01710-17\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2211_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10461-017-1951-y","volume":"22","author":"A Abaasa","year":"2018","unstructured":"Abaasa A, Hendrix C, Gandhi M, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22(4):1165\u201373.","journal-title":"AIDS Behav"},{"issue":"6","key":"2211_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509\u201318.","journal-title":"N Engl J Med"},{"issue":"4","key":"2211_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1310\/hct0904-238","volume":"9","author":"TJ Podsadecki","year":"2008","unstructured":"Podsadecki TJ, Vrijens BC, Tousset EP, et al. \u201cWhite coat compliance\u201d limits the reliability of therapeutic drug monitoring in HIV-1 infected patients. HIV Clin Trials. 2008;9(4):238\u201346.","journal-title":"HIV Clin Trials."},{"issue":"1","key":"2211_CR15","doi-asserted-by":"publisher","first-page":"20642","DOI":"10.7448\/IAS.19.1.20642","volume":"19","author":"A van der Straten","year":"2016","unstructured":"van der Straten A, Brown ER, Marrazzo JM, et al. Divergent adherent estimates with pharmacokinetic and behavioral measures in the MTN-003 (VOICE) Study. J Int AIDS Soc. 2016;19(1):20642. \n                    https:\/\/doi.org\/10.7448\/IAS.19.1.20642\n                    \n                  .","journal-title":"J Int AIDS Soc."},{"issue":"3","key":"2211_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/infdis\/jiv333","volume":"213","author":"JY Dai","year":"2016","unstructured":"Dai JY, Hendrix CW, Richardson BA, et al. Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study. J Infect Dis. 2016;213(3):335\u201342.","journal-title":"J Infect Dis"},{"key":"2211_CR17","doi-asserted-by":"publisher","first-page":"18505","DOI":"10.7448\/IAS.16.1.18505","volume":"16","author":"C Woodsong","year":"2013","unstructured":"Woodsong C, MacQueen K, Amico KR, et al. Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc. 2013;16:18505. \n                    https:\/\/doi.org\/10.7448\/IAS.16.1.18505\n                    \n                  .","journal-title":"J Int AIDS Soc."},{"issue":"1","key":"2211_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.contraception.2006.10.012","volume":"76","author":"AR Wallace","year":"2007","unstructured":"Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53\u20136.","journal-title":"Contraception."},{"issue":"11","key":"2211_CR19","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1097\/OLQ.0b013e31822e6160","volume":"38","author":"LL Katzen","year":"2011","unstructured":"Katzen LL, Fernandez-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis. 2011;38(11):1050\u20135.","journal-title":"Sex Transm Dis"},{"issue":"5","key":"2211_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/OLQ.0b013e31824790bb","volume":"39","author":"TR Moench","year":"2012","unstructured":"Moench TR, O\u2019Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012;39(5):335\u201340.","journal-title":"Sex Transm Dis"},{"issue":"9","key":"2211_CR21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/OLQ.0b013e3182641f08","volume":"39","author":"A Hemmerling","year":"2012","unstructured":"Hemmerling A, Harrison WG, Brown JM, et al. Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. Sex Transm Dis. 2012;39(9):710\u20132.","journal-title":"Sex Transm Dis"},{"issue":"6","key":"2211_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/OLQ.0b013e3181972397","volume":"36","author":"MN Austin","year":"2009","unstructured":"Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis. 2009;36(6):368\u201371.","journal-title":"Sex Transm Dis"},{"issue":"22","key":"2211_CR23","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"2211_CR24","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1007\/s10461-017-1959-3","volume":"22","author":"A Carballo-Di\u00e9guez","year":"2018","unstructured":"Carballo-Di\u00e9guez A, Lentz C, Giguere R, et al. Rectal douching associated with receptive anal intercourse: a literature review. AIDS Behav. 2018;22(4):1288\u201394.","journal-title":"AIDS Behav"},{"key":"2211_CR25","unstructured":"Weld ED, Fuchs E, Marzinke M, et al. Tenofovir enema as HIV PrEP for receptive anal intercourse: safety, pharmacokinetics, pharmacodynamics and acceptability (DREAM-01) [5647]. Presented at: 9th International AIDS Society Conference on HIV Science; Paris, 2017."},{"key":"2211_CR26","unstructured":"Bluewater Biosciences, Inc., ON, Canada. ColiplateTM A quantitative 24-hour test for Coliforms and E. Coli manual."},{"key":"2211_CR27","unstructured":"World Health Organization (WHO). Guidelines for drinking-water quality. 3rd Edition. \n                    http:\/\/www.who.int\/water_sanitation_health\/publications\/2011\/wsh_vol1_1and2_addenda.pdf?ua=1\n                    \n                  . Accessed 24 May 2018."},{"key":"2211_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/(SICI)1098-2256(1998)13:2<157::AID-TOX7>3.0.CO;2-6","volume":"13","author":"R Lifshitz","year":"1997","unstructured":"Lifshitz R, Joshi R. Comparison of the novel Coliplate kit and the standard membrane filter technique for enumerating total coliforms and Escherichia coli bacteria in water. Environ Toxicol Water Quality. 1997;13:157\u201364.","journal-title":"Environ Toxicol Water Quality."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10461-018-2211-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-018-2211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-018-2211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T12:19:13Z","timestamp":1589717953000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10461-018-2211-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["2211"],"URL":"https:\/\/doi.org\/10.1007\/s10461-018-2211-5","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"3 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"CWH has research contracts with ViiV\/GSK and the Bill and Melinda Gates Foundation. WSA, RPB JB, JEJ, EW, EJF, and MAM declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Within this study, all samples were collected following informed consent under Johns Hopkins University School of Medicine IRB-approved protocols.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}